NEW YORK (GenomeWeb News) – Sense Proteomic has spun out of parent firm Procognia to form a stand-alone company that will focus on using a protein array platform aimed at discovering biomarkers for cancer and auto-immune diseases.
 
The Maidenhead, UK-based company has turned to the private equity investment company Apax Partners for financial backing.
 
Financial details of the investment and the spin out were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.